Mammary Cell News Volume 15.46 | Nov 23 2023

    By
    Bob
    -
    0
    70








    2023-11-23 | MCN 15.46


    Mammary Cell News by STEMCELL Technologies
    Vol. 15.46 – 23 November, 2023
    TOP STORY

    IGF2BP2 Drives Cell Cycle Progression in Triple-Negative Breast Cancer by Recruiting EIF4A1 to Promote the m6A-Modified CDK6 Translation Initiation Process

    Investigators found that IGF2BP2 was highly expressed in TNBC due to the lower methylation level in its promoter region.
    [Advanced Science]

    Full Article
    Request a free copy of this wallchart for a quick reference on breast cancer subtypes and signaling pathways.
    PUBLICATIONSRanked by the impact factor of the journal

    Identification of a Targetable JAK-STAT Enriched Androgen Receptor and Androgen Receptor Splice Variant Positive Triple-Negative Breast Cancer Subtype

    Scientists showed that a cohort of TNBC not only expressed androgen receptor (AR) at a much higher rate, but also expressed AR splice variants, further subclassifying luminal AR-TNBC.
    [Cell Reports]

    Full ArticleGraphical Abstract

    The p53/ZEB1-PLD3 Feedback Loop Regulates Cell Proliferation in Breast Cancer

    Investigators demonstrated that phospholipase D3 (PLD3) and miR-6796 are co-expressed in breast cancer. PLD3 could bind with CDK1 and inhibit its expression, leading to mitotic arrest and inhibiting breast cancer proliferation.
    [Cell Death & Disease]

    Full Article

    TNFRSF19 Promotes Endoplasmic Reticulum Stress-Induced Paraptosis via the Activation of the MAPK Pathway in Triple-Negative Breast Cancer Cells

    Scientists demonstrated that the upregulation of TNFRSF19 functioned as a tumor suppressor in TNBC by stimulating paraptosis through the activation of the MAPK pathway-mediated endoplasmic reticulum stress.
    [Cancer Gene Therapy]

    AbstractGraphical Abstract

    YTHDF1 Enhances Stemness and Chemoresistance in Triple-Negative Breast Cancer Cells by Upregulating SIAH2

    Knockdown of YTHDF1 and SIAH2, or overexpression of seven in absentia homology 2 (SIAH2) in vitro and in vivo, was conducted to evaluate the impact of changes in YTHDF1 and SIAH2 expression on TNBC cell proliferation, apoptosis, stemness, drug resistance, and Hippo pathway gene expression.
    [Molecular Carcinogenesis]

    Full Article

    LncRNA SEMA3B-AS1 Suppresses the Tumor-Initiating Characteristics of Triple Negative Breast Cancer via Engaging in MLL4-Mediated H3K4 Trimethylation

    Researchers found that low expression of lncRNA SEMA3B-AS1 correlated with unfavorable survival in breast cancer patients. SEMA3B-AS1 was also downregulated in TNBC and linked to advanced tumor stage.
    [Molecular Carcinogenesis]

    Abstract

    Efficacy of Futibatinib, an Irreversible Fibroblast Growth Factor Receptor Inhibitor, in FGFR-Altered Breast Cancer

    The authors elucidated the efficacy of futibatinib in breast cancer and identified the molecular features associated with its antitumor activity.
    [Scientific Reports]

    Full Article

    Inhibition of Pard3 Promotes Breast Cancer Metastasis via the USP28 Mediated Deubiquitination of Snail1

    Investigators found that Pard3 levels were down-regulated in breast cancer (BC) cells and tissues. Pard3 down-regulation was associated with the TNM stage of BC.
    [Heliyon]

    Full Article

    lncRNA MIAT Promotes Luminal B Breast Cancer Cell Proliferation, Migration, and Invasion In Vitro

    Researchers used UALCAN database analysis to find high expression of lncRNA MIAT in luminal breast cancer (BC) tissues and also confirmed high levels of lncRNA myocardial infarction-associated transcripts (MIAT) expression in luminal B BC tissues and cells.
    [Journal of Applied Genetics]

    Abstract
    Virtual Conference Exhibition: Organoids
    REVIEWS

    Crosstalk and Plasticity Driving between Cancer-Associated Fibroblasts and Tumor Microenvironment: Significance of Breast Cancer Metastasis

    Scientists summarize the inhibitory effects of different natural compounds on targeting cancer-associated fibroblasts and the advantages of different drug combinations.
    [Journal of Translational Medicine]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

    BeiGene, Ltd. and Ensem Therapeutics, Inc. announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.
    [BeiGene, Ltd.]

    Press Release
    FEATURED EVENT

    2023 San Antonio Breast Cancer Symposium

    December 5 – 9, 2023
    San Antonio, Texas, United States

    > See All Events

    JOB OPPORTUNITIES

    Assistant Professor Position – 3D Tissue Organoids

    Swammerdam Institute for Life Sciences – Amsterdam, Netherlands

    Postdoctoral Fellowships – Cancer Research

    NIH National Cancer Institute – Bethesda, Maryland, United States

    Staff Scientist – Translational Sciences

    Baylor College of Medicine – Houston, Texas, United States

    Scientist Positions – Pharmaceutical Sciences

    China Pharmaceutical University – Nanjing, Jiangsu, China

    Postdoctoral Associate – Breast Cancer Metastases

    Baylor College of Medicine – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2